
A promising new treatment: A clinical trial involving 61 patients with advanced pancreatic cancer found that tumors shrank or disappeared in nearly 61% of those receiving the drug daraxonrasib combined with chemotherapy.
Encouraging survival results: Nearly 77% of patients were alive one year after beginning treatment, compared with historical survival rates of roughly 40% to 45% among patients receiving conventional chemotherapy.
More research is needed: Although the results represent a potentially major advance, researchers caution that the study was relatively small and did not directly compare the new combination with chemotherapy alone.
A new approach to treating pancreatic cancer is generating excitement among cancer researchers after a clinical trial found that an experimental combination of a targeted drug and chemotherapy produced unusually strong results in patients with advanced disease.
The drug, called daraxonrasib, is designed to interfere with genetic mutations that fuel the growth of pancreatic tumors. When combined with two commonly used chemotherapy drugs, it produced substantial tumor shrinkage in a majority of patients, according to findings presented November 20 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Author: Mark Huffman
Source: Consumer Affairs
Posted: 2026-11-20 13:55:28









